Tracy Valorie
SEATTLE—Visus Therapeutics Inc., a clinical-stage pharmaceutical company developing innovative ophthalmic therapies, has appointed Tracy Valorie, former senior vice president and general manager, U.S. ophthalmology Rx and surgical at Bausch + Lomb, and Dwight Moxie, senior vice president, general counsel and corporate secretary at Revance Therapeutics, to its board of directors. “I am very pleased to welcome Tracy Valorie and Dwight Moxie to Visus Therapeutics’ board of directors,” Ben Bergo, co-founder and chief executive officer, said in an announcement from the company.
 
“Both of these renowned leaders possess expertise across many industries and will be invaluable as we continue to grow our portfolio of novel compounds and advance our lead program, Brimochol, in development for the treatment of presbyopia. I look forward to their strategic insights and contributions to achieve our mission of dramatically improving patients’ lives by developing differentiated best-in-class ophthalmic therapies.”
 
Valorie brings deep expertise with 25 years of experience in the pharmaceutical and biotech industries spanning strategic business counsel, commercial development, brand and customer marketing, and clinical development and research. Prior to her positions at Bausch + Lomb, she held numerous leadership positions at Pfizer, where she led commercial development for the company’s global ophthalmology franchise, including Xalatan and Xalacom for glaucoma.
 

Dwight Moxie
“I am honored to join Visus Therapeutics’ board of directors and am looking forward to working with this talented and capable team,” Valorie said. “Brimochol has the potential to be a real-world solution for people living with presbyopia, and I am excited to be an integral part of the organization developing a best-in-class pipeline of ophthalmic products under Ben’s leadership.”
 
Moxie leads legal, governance and compliance at Revance Therapeutics, and brings more than two decades of experience in the biopharmaceutical and health care sectors, advising and supporting companies developing and commercializing novel drugs. Previously, he served as the vice president, deputy general counsel at Ultragenyx and held various legal counsel positions at Allergan and GlaxoSmithKline.